EGFR and neoplasm: One clinical study used a cocktail of CAR T therapies in patients with terminal CCA with the sequential infusion of epidermal growth factor receptor (EGFR)-specific and CD133-specific CAR T cells, which effectively inhibited tumor progression(Figure 1B) (42).